Colistin use in critically ill neonates: A case–control study

Basit Öğe Kaydı
dc.authorid0000-0002-1472-9199en_US
dc.authorid0000-0002-0760-5681en_US
dc.contributor.authorİpek, Mehmet Şah
dc.contributor.authorAktar, Fesih
dc.contributor.authorOkur, Nilufer
dc.contributor.authorÇelik, Muhittin
dc.contributor.authorÖzbek, Erdal
dc.date.accessioned2024-03-25T13:05:57Z
dc.date.available2024-03-25T13:05:57Z
dc.date.issued2017en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground The aim of this study was to assess the safety and efficacy of colistin use in critically ill neonates. Methods This was a case–control study that included newborn infants with proven or suspected nosocomial infections between January 2012 and October 2015, at two centers in Diyarbakir, Turkey. The clinical and laboratory characteristics and outcomes of patients who received colistin therapy were reviewed and compared to patients who were treated with antimicrobial agents other than colistin during the same period. Results Forty-seven cases who received intravenous colistin (colistin group) and 59 control patients (control group) were included. There were no significant differences between the groups regarding outcomes and nephrotoxicity, including acute renal failure. Colistin therapy was associated with significantly reduced serum magnesium (1.38 ± 0.39 mg/dL vs. 1.96 ± 0.39 mg/dL, p < 0.001) and hypokalemia (46.8% vs. 25.4%, p = 0.026). The patients who received colistin also had longer hospital stays (43 (32–70) days vs. 39 (28–55) days, p = 0.047), a higher rate of previous carbapenem exposure (40.4% vs. 11.9%, p = 0.001), and a higher age at the onset of infection (13 (10–21) days vs. 11 (9–15) days, p = 0.03). Conclusion This study showed that colistin was both effective and safe for treating neonatal infections caused by multidrug-resistant gram-negative bacteria. However, intravenous colistin use was significantly associated with hypomagnesemia and hypokalemia.en_US
dc.identifier.citationİpek, M. Ş., Aktar, F., Okur, N., Çelik, M. ve Özbek, E. (2017). Colistin use in critically ill neonates: A case–control study. Pediatrics and Neonatology, 58(6), 490-496.en_US
dc.identifier.doi10.1016/j.pedneo.2016.10.002
dc.identifier.endpage496en_US
dc.identifier.issn1875-9572
dc.identifier.issue6en_US
dc.identifier.pmid28501490
dc.identifier.scopus2-s2.0-85019092435
dc.identifier.scopusqualityQ2
dc.identifier.startpage490en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1875957217301766?via%3Dihub
dc.identifier.urihttps://hdl.handle.net/11468/13708
dc.identifier.volume58en_US
dc.identifier.wosWOS:000424735700004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAktar, Fesih
dc.language.isoenen_US
dc.publisherElsevier (Singapore) Pte Ltden_US
dc.relation.ispartofPediatrics and Neonatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectColistinen_US
dc.subjectGram-negative bacteriaen_US
dc.subjectNosocomial infectionen_US
dc.subjectMulti-drug resistanten_US
dc.subjectNeonateen_US
dc.titleColistin use in critically ill neonates: A case–control studyen_US
dc.titleColistin use in critically ill neonates: A case–control study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Colistin use in critically ill neonates_ A&nbsp;case-control study.pdf
Boyut:
376.3 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu